# FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

> **NCT00806663** · PHASE2 · COMPLETED · sponsor: **Central European Society for Anticancer Drug Research** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** sunitinib added to FOLFIRI

## Key facts

- **NCT ID:** NCT00806663
- **Lead sponsor:** Central European Society for Anticancer Drug Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-07
- **Final completion:** 2011-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00806663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00806663, "FOLFIRI and Sunitinib in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00806663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*